News|Articles|November 18, 2026

Your Questions Answered: GLP-1 Deals, FDA Approvals, and Manufacturing Buildout

Listen
0:00 / 0:00

Key Takeaways

  • Blackstone funds up to $1.5B of berobenatide development through 2028; Pfizer retains full control and all ownership, while Blackstone earns approval- and sales-linked milestones without drug rights.
  • Johnson & Johnson acquired Ollin for OLN324 and separately secured $750M Blackstone Phase III funding for milestones and single-digit royalties, mirroring off–balance sheet late-stage financing structures.
SHOW MORE

The month's biggest moves — from Pfizer and Blackstone's obesity co-funding agreement to Lilly's $3.5B Pennsylvania groundbreaking — answered in plain language.

What did Pfizer and Blackstone agree to, and what does each side get out of it?

Pfizer and Blackstone Life Sciences signed a co-funding agreement for berobenatide, Pfizer's investigational monthly GLP-1 receptor agonist for chronic weight management. Blackstone-managed funds will cover up to $1.5 billion of development costs through 2028. In return, Blackstone is eligible for milestone payments tied to U.S. approval of monthly injectable dosing and to certain commercial sales targets.

Crucially, Blackstone receives no rights or ownership in the drug. Pfizer keeps full operational control over all development decisions. The deal gives Pfizer a way to advance an expensive Phase III-stage obesity program while keeping some of that capital exposure off its own books.

Berobenatide is not approved. Pfizer has 10 ongoing or planned Phase III trials for the drug in 2026, targeting obesity and related conditions including knee osteoarthritis and obstructive sleep apnea. In the Vesper-3 study it produced up to 12.3% placebo-adjusted weight loss at 28 weeks.

What deals did J&J, Lilly, AmyriAD, and Sanofi announce this week?

Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2B upfront plus up to ~$1.125B in milestones. The asset is OLN324, a late-stage bispecific antibody for retinal disease. Separately, Blackstone Life Sciences will pay J&J $750M to fully fund OLN324's Phase III development in exchange for certain milestones and single-digit royalties — a structure echoing the Pfizer deal announced the same week.

Eli Lilly acquired Calytrix Bio for up to $1.5B to gain an investigational biparatopic antibody targeting essential thrombocythemia and myelofibrosis driven by mutant calreticulin — blood cancers with limited disease-modifying options today.

AmyriAD Therapeutics acquired AD04 from ADvantage Therapeutics (terms undisclosed). AD04 is a subcutaneously administered, Phase IIb-ready candidate for mild Alzheimer's disease that acts through peripheral inflammation to reduce neuroinflammation in the brain. It joins AmyriAD's existing program for moderate Alzheimer's, covering both disease stages.

Sanofi entered a multi-target collaboration and license with Seawolf Therapeutics (up to $1.2B in milestones plus tiered royalties) for the Trident platform — a redosable lipid nanoparticle system for delivering DNA payloads, targeting bleeding disorders and other indications.

What did Gilead's Ebola licensing deals do — and why do they matter for access?

Gilead signed royalty-free voluntary licenses with three generic manufacturers — Dr. Reddy's Laboratories, Eva Pharma, and Ferozsons Laboratories — covering obeldesivir as a potential post-exposure prophylaxis for Ebola Bundibugyo virus disease. The licenses cover 127 mostly low- and lower-middle-income countries, including every African nation with reported cases in the current outbreak.

The unusual aspect of this deal is its timing: obeldesivir is not approved anywhere for filovirus prevention, and clinical trial results aren't in yet. Gilead is setting up manufacturing and supply capacity now, before data, so that if the drug works and wins regulatory authorization, manufacturers can move immediately rather than waiting months or years to negotiate access arrangements after the fact.

"These agreements reflect our commitment to preparing for future access while clinical research is ongoing."

— Jaime McCoy, VP of Gilead Patient Solutions

Gilead has also donated more than 38,000 vials of remdesivir for investigational use across the DRC, Uganda, and Kenya, and is updating its remdesivir licenses to cover filovirus disease pending results from a separate WHO-sponsored trial.

FDA Approvals

What did the FDA approve this week, and why are these approvals significant?

Two approvals came through this week, both addressing conditions where current treatments leave patients with meaningful unmet needs.

Cosentyx (secukinumab) for polymyalgia rheumatica — Novartis. The FDA approved the 150 mg dose for adults with PMR who have had an inadequate response to corticosteroids or cannot tolerate a steroid taper. This is the first anti-IL-17 biologic approved for PMR, a condition that mainly affects adults over 50 and has been treated almost exclusively with long-term steroids — which cause relapses in up to 40% of patients in the first year and carry risks of osteoporosis, cardiovascular disease, and diabetes. In the Phase III Replenish trial, secukinumab doubled the likelihood of sustained remission and helped patients taper off steroids entirely.

"For too long, treatment options beyond glucocorticoids have been limited."

— Prof. John Stone, global principal investigator, Replenish trial

Wilserdly (giredestrant) with everolimus for ESR1-mutated breast cancer — Roche. The FDA approved the combination for adults with ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer that progressed on prior CDK4/6 inhibitor therapy. ESR1 mutations drive resistance in up to 40% of hormone receptor-positive metastatic cases. In the Phase III evERA trial, the combination cut the risk of progression or death by 62% versus standard endocrine therapy plus everolimus (HR 0.38). Notably, it's an all-oral regimen.

Roche also has Priority Review for an adjuvant giredestrant application in early-stage breast cancer (stages I–III), with a PDUFA date of November 30. If approved, it would be the first new adjuvant endocrine therapy for breast cancer in more than 20 years.

Cosentyx: first anti-IL-17 for PMRWilserdly: 62% reduction in PD or deathAdjuvant PDUFA: Nov 30

What is Lilly building in Pennsylvania, and what does it tell us about where the GLP-1 race is headed?

Eli Lilly broke ground on a $3.5 billion manufacturing facility in Fogelsville, Pennsylvania, expected to be operational by 2031. The site will produce injectable medicines and devices, with added capacity specifically for next-generation obesity treatments — including retatrutide, Lilly's investigational once-weekly triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously.

The Pennsylvania facility is one of four injectable and device sites Lilly has announced as part of a broader $50 billion U.S. manufacturing expansion — 10 new sites announced since 2020. It will create approximately 850 permanent high-wage roles and 2,000 construction jobs, and targets LEED Gold certification.

The strategic logic is straightforward: manufacturing capacity, not science, is now the primary constraint on how quickly next-generation obesity drugs reach patients. Lilly is building the supply chain before retatrutide is approved — placing a $3.5B bet that it will be.

What did Moderna announce at its analyst day, and is the pivot to oncology working?

At its November 12 Analyst Day, Moderna updated its growth outlook and laid out an oncology-centered strategy for the next several years.

On the numbers: Moderna now expects 2026 revenue growth of 15–25%, up from an earlier outlook of up to 10%, with gross margin expanding roughly 10 percentage points. Annual cash costs are expected to run $4.0–4.5B from 2027 through 2030, primarily driven by oncology investment.

The oncology headline is its individualized neoantigen therapy, intismeran autogene, developed with Merck and combined with Keytruda. The Phase III Interpath-001 trial in resected high-risk melanoma met its primary endpoint: the combination reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38%, compared with Keytruda alone. Results were published in the New England Journal of Medicine. Commercialization is pending regulatory approval.

Beyond the flagship program, Moderna has three additional cancer antigen therapies in early clinical development. The company is also preparing a broader commercial launch of its influenza vaccine for the 2027–28 respiratory season, and has long-term vaccine partnership agreements in the UK, Canada, Australia, Mexico, and Taiwan.

What happened to the FDA's Commissioner's National Priority Voucher program?

The FDA has effectively shelved the Commissioner's National Priority Voucher (CNPV) program, according to six sources and internal documents cited by Reuters. The program, launched in June 2025 under then-Commissioner Marty Makary, was designed to cut review times to one to two months for drugs addressing national priorities — but it also drew criticism for potentially allowing political influence over drug approvals.

Since Makary left in May, no new vouchers have been awarded. The FDA has had no permanent commissioner since his departure, and the political appointee executive council that drove expedited decisions under the program has reportedly gone dormant. Sources say companies submitting applications have been informally told the FDA is no longer advancing them.

22 drugs received vouchers before the program stalled, 12 of which have since been approved — five of them after Makary's departure, without council review. For the nine drugs still in the pipeline, oversight has reportedly returned to career FDA scientists following standard timelines.

"The worst of both worlds" — combining political-influence risks with limited practical benefit, since many qualifying drugs could have used existing expedited pathways.

— Holly Fernandez Lynch, University of Pennsylvania health policy professor

HHS has disputed the characterization, saying the pilot is ongoing and that the FDA is reviewing feedback from a June public hearing. The agency has not responded to questions about whether a new program coordinator has been appointed.


Related to this article